
Neuro-oncologist

No OPD information available
Astrocytoma
Glioblastoma
Glioma
Gliomatosis Cerebri
Brain Tumor
Cerebral Hypoxia
Embryonal Tumor with Multilayered Rosettes
Medulloblastoma
Spinal Tumor
Lawrence M. Cher is a male medical professional who specializes in treating various brain and spinal tumors such as astrocytoma, glioblastoma, and medulloblastoma. He helps patients with conditions like cerebral hypoxia and gliomatosis cerebri.
Lawrence M. Cher uses special skills and treatments to care for patients with brain and spinal tumors. He communicates clearly with patients, explaining their conditions and treatments in a way that is easy to understand. Patients trust him because he listens to their concerns and provides compassionate care.
To stay updated with the latest medical knowledge and research, Lawrence M. Cher regularly attends conferences and reads scientific journals. He collaborates with other medical professionals to share knowledge and improve patient care.
Lawrence M. Cher has positive relationships with colleagues and works well with other medical professionals. He values teamwork and believes that collaborating with others leads to better outcomes for patients.
His work has made a positive impact on patients' lives by providing effective treatments for brain and spinal tumors. Patients have seen improvements in their health and quality of life under his care.
One of Lawrence M. Cher's notable publications is "Antibody drug conjugates for glioblastoma: current progress towards clinical use," showing his commitment to advancing treatments for brain tumors. He is also involved in a clinical trial studying the safety and tolerability of a new treatment for recurrent glioblastoma, demonstrating his dedication to finding innovative solutions for patients.
In summary, Lawrence M. Cher is a skilled and compassionate medical professional who specializes in treating brain and spinal tumors. He stays updated with the latest research, collaborates with colleagues, and has a positive impact on patients' lives through his work.
Enrollment Status: Unknown
Published: August 17, 2022
Intervention Type: Drug
Study Drug: TTAC-0001+Pembrolizumab
Study Phase: Phase 1
